Peter Eirew

Staff Scientist
LinkedIn

Dr Peter Eirew is a Staff Scientist carrying out research in cancer evolution in Dr Sam Aparicio’s lab at BC Cancer. Dr Eirew has a varied academic and work background, with degrees in Physics (Cambridge University, UK), MSc Molecular Medicine (Imperial College London), Masters in Business Administration (Manchester Business School), and PhD research identifying stem cells in the human breast (University of British Columbia, supervisor Dr Connie Eaves). He is part of the multi-disciplinary BC Cancer Personalized OncoGenomics (POG) Program, using next generation sequencing and other omics to guide clinical decision making in cancer patients. He also spent 17 years in the financial sector, during which he co-headed a group trading bonds, currencies and derivatives. Outside work, Peter enjoys skiing with his family, tennis and playing piano.

Dr Eirew received the Governor General of Canada Gold Medal in 2012.

Papers

Clonal fitness inferred from time-series modelling of single-cell cancer genomes.

Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing.

Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses.

Scalable whole-genome single-cell library preparation without preamplification.

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.

Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.

A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation.

DNA barcoding reveals diverse growth kinetics of human breast tumour subclones in serially passaged xenografts.

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.

Clonal analysis via barcoding reveals diverse growth and differentiation of transplanted mouse and human mammary stem cells.

The omics of triple-negative breast cancers.

A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability.